{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:23:01Z","timestamp":1791026581035,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,10,20]],"date-time":"2013-10-20T00:00:00Z","timestamp":1382227200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s00280-013-2317-4","type":"journal-article","created":{"date-parts":[[2013,10,19]],"date-time":"2013-10-19T09:50:15Z","timestamp":1382176215000},"page":"61-68","source":"Crossref","is-referenced-by-count":3,"title":["Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study"],"prefix":"10.1007","volume":"73","author":[{"given":"Anne","family":"Floquet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad\u00e9la\u00efde","family":"Doussau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Brouste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Cany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Dutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Mathoulin-P\u00e9lissier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,20]]},"reference":[{"issue":"2","key":"2317_CR1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0368-2315(05)82707-3","volume":"34","author":"B Tretarre","year":"2005","unstructured":"Tretarre B, Remontet L, Menegoz F et al (2005) Ovarian cancer: incidence and mortality in France. J Gynecol Obstet Biol Reprod (Paris) 34(2):154\u2013161","journal-title":"J Gynecol Obstet Biol Reprod (Paris)"},{"issue":"Suppl 8","key":"2317_CR2","doi-asserted-by":"crossref","first-page":"viii7","DOI":"10.1093\/annonc\/mdi961","volume":"16","author":"A Bois du","year":"2005","unstructured":"du Bois A, Quinn M, Thigpen T et al (2005) 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International gynecologic cancer intergroup ovarian cancer consensus conference (GCIG OCCC 2004). Ann Oncol 16(Suppl 8):viii7\u2013viii12","journal-title":"Ann Oncol"},{"issue":"20","key":"2317_CR3","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","volume":"28","author":"E Pujade-Lauraine","year":"2010","unstructured":"Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al (2010) Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28(20):3323\u20133329","journal-title":"J Clin Oncol"},{"issue":"9375","key":"2317_CR4","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","volume":"361","author":"MK Parmar","year":"2003","unstructured":"Parmar MK, Ledermann JA, Colombo N et al (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial. Lancet 361(9375):2099\u20132106","journal-title":"Lancet"},{"issue":"29","key":"2317_CR5","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","volume":"24","author":"J Pfisterer","year":"2006","unstructured":"Pfisterer J, Plante M, Vergote I et al (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24(29):4699\u20134707","journal-title":"J Clin Oncol"},{"issue":"14","key":"2317_CR6","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19(14):3312\u20133322","journal-title":"J Clin Oncol"},{"key":"2317_CR7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2147\/TCRM.S3348","volume":"6","author":"G Ferrandina","year":"2010","unstructured":"Ferrandina G, Corrado G, Licameli A et al (2010) Pegylated liposomal doxorubicin in the management of ovarian cancer. Ther Clin Risk Manag 6:463\u2013483","journal-title":"Ther Clin Risk Manag"},{"key":"2317_CR8","doi-asserted-by":"crossref","unstructured":"Gladieff L, Ferrero A, De RG et al (2012) Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Ann Oncol 23(5):1185\u20131189","DOI":"10.1093\/annonc\/mdr441"},{"issue":"3","key":"2317_CR9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2009.11.026","volume":"116","author":"M Markman","year":"2010","unstructured":"Markman M, Moon J, Wilczynski S et al (2010) Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol 116(3):323\u2013325","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2317_CR10","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ygyno.2009.04.037","volume":"114","author":"P Power","year":"2009","unstructured":"Power P, Stuart G, Oza A et al (2009) Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study. Gynecol Oncol 114(3):410\u2013414","journal-title":"Gynecol Oncol"},{"issue":"15","key":"2317_CR11","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","volume":"22","author":"M Markman","year":"2004","unstructured":"Markman M, Markman J, Webster K et al (2004) Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 22(15):3120\u20133125","journal-title":"J Clin Oncol"},{"issue":"1","key":"2317_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334(1):1\u20136","journal-title":"N Engl J Med"},{"issue":"9","key":"2317_CR13","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","volume":"92","author":"MJ Piccart","year":"2000","unstructured":"Piccart MJ, Bertelsen K, James K et al (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92(9):699\u2013708","journal-title":"J Natl Cancer Inst"},{"key":"2317_CR14","first-page":"abs 954","volume":"17","author":"A Owainati","year":"1998","unstructured":"Owainati A, Zalupski M, Shields A, Hussain M, Philip PA (1998) Phase I study of liposomal doxorubicin (doxil) and cyclophosphamide in solid tumors. J Clin Oncol 17:abs 954","journal-title":"J Clin Oncol"},{"issue":"9","key":"2317_CR15","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/sj.bjc.6604026","volume":"97","author":"I Ray-Coquard","year":"2007","unstructured":"Ray-Coquard I, Paraiso D, Guastalla JP et al (2007) Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group. Br J Cancer 97(9):1200\u20131205","journal-title":"Br J Cancer"},{"issue":"3","key":"2317_CR16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"2317_CR17","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1200\/JCO.2000.18.8.1733","volume":"18","author":"GJ Rustin","year":"2000","unstructured":"Rustin GJ, Nelstrop AE, Bentzen SM, Bond SJ, McClean P (2000) Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol 18(8):1733\u20131739","journal-title":"J Clin Oncol"},{"issue":"2","key":"2317_CR18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1006\/gyno.2001.6272","volume":"82","author":"PG Rose","year":"2001","unstructured":"Rose PG, Maxson JH, Fusco N, Mossbruger K, Rodriguez M (2001) Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol 82(2):323\u2013328","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2317_CR19","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3816\/CBC.2005.n.017","volume":"6","author":"B Overmoyer","year":"2005","unstructured":"Overmoyer B, Silverman P, Holder LW, Tripathy D, Henderson IC (2005) Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. Clin Breast Cancer 6(2):150\u2013157","journal-title":"Clin Breast Cancer"},{"issue":"35","key":"2317_CR20","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.1200\/JCO.2009.22.7504","volume":"27","author":"ME Trudeau","year":"2009","unstructured":"Trudeau ME, Clemons MJ, Provencher L et al (2009) Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. J Clin Oncol 27(35):5906\u20135910","journal-title":"J Clin Oncol"},{"issue":"4","key":"2317_CR21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/01.coc.0000224542.80581.46","volume":"29","author":"H Bourgeois","year":"2006","unstructured":"Bourgeois H, Joly F, Pujade-Lauraine E et al (2006) Phase I study of pegylated liposomal doxorubicin in combination with ifosfamide in pretreated ovarian cancer patients. Am J Clin Oncol 29(4):399\u2013404","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"2317_CR22","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/annonc\/mdh025","volume":"15","author":"HW Bokkel ten","year":"2004","unstructured":"ten Bokkel HW, Lane SR, Ross GA (2004) Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 15(1):100\u2013103","journal-title":"Ann Oncol"},{"issue":"Suppl 18","key":"2317_CR23","first-page":"LBA5002","volume":"30","author":"E Pujade-Lauraine","year":"2013","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B et al (2013) AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 30(Suppl 18):LBA5002","journal-title":"J Clin Oncol"},{"issue":"1","key":"2317_CR24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.critrevonc.2009.08.004","volume":"73","author":"S Pignata","year":"2010","unstructured":"Pignata S, Lauraine EP, du Bois A, Pisano C (2010) Pegylated liposomal doxorubicin combined with carboplatin: a rational treatment choice for advanced ovarian cancer. Crit Rev Oncol Hematol 73(1):23\u201330","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"2317_CR25","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ygyno.2007.08.008","volume":"107","author":"A Bois du","year":"2007","unstructured":"du Bois A, Pfisterer J, Burchardi N et al (2007) Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol Oncol 107(3):518\u2013525","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2317_CR26","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ygyno.2007.08.075","volume":"108","author":"DS Alberts","year":"2008","unstructured":"Alberts DS, Liu PY, Wilczynski SP et al (2008) Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group protocol S0200). Gynecol Oncol 108(1):90\u201394","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2317_CR27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/annonc\/mdq352","volume":"22","author":"A Poveda","year":"2011","unstructured":"Poveda A, Vergote I, Tjulandin S et al (2011) Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6\u201312\u00a0months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 22(1):39\u201348","journal-title":"Ann Oncol"},{"issue":"9","key":"2317_CR28","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1634\/theoncologist.2013-0126","volume":"18","author":"JM Gibson","year":"2013","unstructured":"Gibson JM, Alzghari S, Ahn C, Trantham H, La-Beck NM (2013) The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials. Oncologist 18(9):1022\u20131031","journal-title":"Oncologist"},{"key":"2317_CR29","doi-asserted-by":"crossref","unstructured":"Handolias D, Quinn M, Foo S et al (2013) Oral cyclophosphamide in recurrent ovarian cancer. Asia Pac J Clin Oncol. doi: 10.1111\/ajco.12074","DOI":"10.1111\/ajco.12074"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2317-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2317-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2317-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T06:13:20Z","timestamp":1596694400000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2317-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,20]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["2317"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2317-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,20]]}}}